Serotonin reduction in post-acute sequelae of viral infection.
Long COVID
PASC
neurocognitive symptoms
platelets
post-viral syndromes
serotonin
thrombocytopenia
type I interferons
vagus nerve
viral persistence
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
received:
04
08
2022
revised:
27
07
2023
accepted:
13
09
2023
medline:
30
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
Post-acute sequelae of COVID-19 (PASC, "Long COVID") pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several hypotheses have been formulated to explain the etiology of PASC, including viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction. Here, we propose a mechanism that links all four hypotheses in a single pathway and provides actionable insights for therapeutic interventions. We find that PASC are associated with serotonin reduction. Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover. Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory. These findings provide a possible explanation for neurocognitive symptoms associated with viral persistence in Long COVID, which may extend to other post-viral syndromes.
Identifiants
pubmed: 37848036
pii: S0092-8674(23)01034-6
doi: 10.1016/j.cell.2023.09.013
pii:
doi:
Substances chimiques
Serotonin
333DO1RDJY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4851-4867.e20Subventions
Organisme : NCI NIH HHS
ID : P30 CA016520
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI045008
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI055400
Pays : United States
Organisme : NHLBI NIH HHS
ID : F31 HL160065
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI141393
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK123733
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA029859
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141003
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI158013
Pays : United States
Organisme : NIA NIH HHS
ID : DP2 AG067492
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK050306
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR069589
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK019525
Pays : United States
Organisme : NIA NIH HHS
ID : DP2 AG067511
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES013508
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests E.J.W. is an advisor for Danger Bio, Janssen, New Limit, Marengo, Pluto Immunotherapeutics Related Sciences, Rubius Therapeutics, Santa Ana Bio, Synthekine, and Surface Oncology. E.J.W. is a founder of and holds stock in Surface Oncology, Danger Bio, and Arsenal Biosciences. N.J.M. reports consulting fees from Endpoint Health Inc and AstraZeneca and receives funding from Quantum Leap Healthcare Collaborative outside of the published work.